Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.36 |
| ▸ | GSK3A | P49840 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 6/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 3/20 | 0.34 |
| ▸ | CDK7 | P50613 | 2/20 | 0.34 |
| ▸ | CDK4 | P11802 | 1/20 | 0.34 |
| ▸ | PLK4 | O00444 | 2/20 | 0.32 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2660858 | 0.84 | GSK3B (0.40) | GSK3BNTRK1SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL2660578 | 0.80 | GSK3B (0.46) | GSK3BNTRK1SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL2660835 | 0.77 | NTRK1 (0.49) | GSK3BNTRK1SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL5583100 | 0.77 | HDAC6 (0.43) | GSK3BNTRK1CYP1A2CYP2C19MEN1 | |
| SCHEMBL2661024 | 0.76 | JAK2 (0.50) | GSK3BNTRK1GSK3ACDK2DYRK1A | |
| SCHEMBL2660083 | 0.75 | FADS1 (0.54) | GSK3BNTRK1SMN1; SMN2JAK2 | |
| SCHEMBL2660218 | 0.75 | PDPK1 (0.54) | GSK3BNTRK1SMN1; SMN2GSK3ACDK2 | |
| SCHEMBL2662113 | 0.75 | MEN1 (0.55) | NTRK1SMN1; SMN2CYP1A2CYP2C19MEN1 | |
| SCHEMBL2662164 | 0.75 | NTRK1 (0.52) | GSK3BNTRK1SMN1; SMN2GSK3AMAPT | |
| SCHEMBL2661484 | 0.73 | NTRK1 (0.50) | GSK3BNTRK1SMN1; SMN2GSK3ACDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301155-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-08 | — | — | US | disclosed |
| US-20110301155-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-08 | — | — | US | disclosed |
| EP-2157859-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | Takeda Pharmaceutical Company Limited (JP) | 2010-03-03 | — | — | EP | disclosed |
| WO-2008156757-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301155-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | GCKR, GCK, KHK | GSK3B 2134/4885NTRK1 1997/4885SMN1; SMN2 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.